98%
921
2 minutes
20
Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterised by hepatic steatosis in the absence of significant alcohol consumption or other specific causes of liver injury. It has become one of the leading causes of liver dysfunction worldwide. However, the precise pathophysiological mechanisms underlying NAFLD remain unclear, and effective therapeutic strategies are still under investigation. Autophagy, a vital intracellular process in eukaryotic cells, enables the degradation and recycling of cytoplasmic components through a membrane trafficking pathway. Recent studies have demonstrated a strong association between impaired or deficient autophagy and the development and progression of NAFLD. Restoring autophagic function may represent a key approach to mitigating hepatocellular injury. Nevertheless, due to the complexity of autophagy regulation and its context-dependent effects on cellular function, therapeutic strategies targeting autophagy in NAFLD remain limited. This review aims to summarise the relationship between autophagy and NAFLD, focusing on autophagy as a central mechanism. We discuss the latest research advances regarding interventions such as diet and exercise, pharmacological therapies (including modern pharmacological therapy and plant-derived compounds), and other approaches (such as hormones, nanoparticles, gut microbiota, and vitamins). Furthermore, we briefly highlight potential autophagy-related molecular targets that may offer novel therapeutic insights for NAFLD management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12383869 | PMC |
http://dx.doi.org/10.3390/biology14080989 | DOI Listing |
Medicine (Baltimore)
September 2025
Department of Medical Technology, Anhui Medical College, Hefei, Anhui, China.
Increasing evidence indicates a potential link between macrophage colony-stimulating factor 1 (CSF1) and macrophage migration inhibitory factor (MIF) with nonalcoholic fatty liver disease (NAFLD). However, the causal relationships remain unclear. This study aims to clarify the causal associations between CSF1, MIF, and NAFLD using Mendelian randomization (MR) analysis.
View Article and Find Full Text PDFGastroenterol Hepatol
September 2025
Balearic Health Service, Mallorca, Spain; ADEMA-Health Group of IUNICS, Balearic Islands, Spain. Electronic address:
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern, particularly among individuals with obesity. While metabolic and behavioral risk factors have been well described, the role of psychosocial determinants, such as weight stigma, remains underexplored.
Objectives: To assess the association between sociodemographic variables, healthy lifestyle behaviors, and internalized weight stigma with MASLD risk in a large cohort of obese workers across Spain.
Diabetes Metab Syndr Obes
August 2025
Department of Otolaryngology, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, People's Republic of China.
Purpose: Obstructive sleep apnea (OSA) contributes to non-alcoholic fatty liver disease (NAFLD) via pathways involving insulin resistance (IR). The triglyceride-glucose (TyG) index, a widely used marker of IR, is associated with both OSA and NAFLD. However, the role of the TyG index in linking OSA to NAFLD remains underexplored.
View Article and Find Full Text PDFJHEP Rep
October 2025
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Background & Aims: Conflicting evidence exists on hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) receiving tenofovir entecavir. We assessed the impacts of the two drugs on the clinical trajectory of CHB at a population level.
Methods: We conducted a retrospective nationwide cohort study using data from Taiwan's National Health Insurance Research Database, including 55,885 patients with CHB who were treatment-naïve aged 30-75 years receiving tenofovir (n = 17,137) or entecavir (n = 38,748) monotherapy for ≥3 months between November 2009 and December 2020, and followed until December 2022.
Diabetes Metab J
September 2025
Department of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea.
Background: This study aimed to investigate the association between adiponectin levels and the incidence of metabolic dysfunction- associated steatotic liver disease (MASLD) and nonalcoholic fatty liver disease (NAFLD), and to explore the predictive value of adiponectin in the onset of these conditions.
Methods: A 17-year follow-up of 35,026 individuals from the Korean Cancer Prevention Study-II biobank cohort (2004-2021) was conducted. Adiponectin levels were categorized into quintiles.